Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/21724
Title: | Data-driven risk identification in phase III clinical trials using central statistical monitoring | Authors: | Timmermans, Catherine Venet, David BURZYKOWSKI, Tomasz |
Issue Date: | 2016 | Publisher: | SPRINGER JAPAN KK | Source: | INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 21 (1), p. 38-45 | Abstract: | Our interest lies in quality control for clinical trials, in the context of risk-based monitoring (RBM). We specifically study the use of central statistical monitoring (CSM) to support RBM. Under an RBM paradigm, we claim that CSM has a key role to play in identifying the "risks to the most critical data elements and processes" that will drive targeted oversight. In order to support this claim, we first see how to characterize the risks that may affect clinical trials. We then discuss how CSM can be understood as a tool for providing a set of data-driven key risk indicators (KRIs), which help to organize adaptive targeted monitoring. Several case studies are provided where issues in a clinical trial have been identified thanks to targeted investigation after the identification of a risk using CSM. Using CSM to build data-driven KRIs helps to identify different kinds of issues in clinical trials. This ability is directly linked with the exhaustiveness of the CSM approach and its flexibility in the definition of the risks that are searched for when identifying the KRIs. In practice, a CSM assessment of the clinical database seems essential to ensure data quality. The atypical data patterns found in some centers and variables are seen as KRIs under a RBM approach. Targeted monitoring or data management queries can be used to confirm whether the KRIs point to an actual issue or not. | Notes: | [Timmermans, Catherine] Catholic Univ Louvain, Inst Stat Biostat & Sci Actuarielles ISBA, Voie Roman Pays 20, Louvain La Neuve, Belgium. [Venet, David] Univ Libre Bruxelles, Inst Rech Interdisciplinaires & Dev Intelligence, Brussels, Belgium. [Burzykowski, Tomasz] Hasselt Univ, Interuniv Inst Biostat & Stat Bioinformat, Diepenbeek, Belgium. [Burzykowski, Tomasz] Int Inst Drug Dev, Louvain La Neuve, Belgium. | Keywords: | clinical trials; multicenter study; risk management; quality assurance;Clinical trials; Multicenter study; Risk management; Quality assurance | Document URI: | http://hdl.handle.net/1942/21724 | ISSN: | 1341-9625 | e-ISSN: | 1437-7772 | DOI: | 10.1007/s10147-015-0877-5 | ISI #: | 000370159000006 | Rights: | © Japan Society of Clinical Oncology 2015 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2017 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art%3A10.1007%2Fs10147-015-0877-5.pdf Restricted Access | Published version | 1.21 MB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
7
checked on Sep 2, 2020
WEB OF SCIENCETM
Citations
14
checked on Aug 11, 2024
Page view(s)
50
checked on Sep 7, 2022
Download(s)
44
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.